The Core Model

The Core Model: A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care develops the innovative core model, an organizational research and design paradigm and economic theory that proposes a collaborative approach to resolving global health issues and improving the productivity of drug development. The model proposes that scientific collaboration does not occur in an unstructured manner, but actually takes place within a highly structured order where knowledge is transferred, integrated and finally translated into commercial products. An understanding of this model will help solve the global pharmaceutical industry´s productivity problems and address important global health care and economic issues.

This book is useful to researchers, advanced students, regulators, and management in pharmaceutical industries, as well as healthcare professionals, those working in health economics, and those interested in scientific innovation processes.

• Explores the current state-of-the-art in the pharmaceutical industry and the global healthcare sector
• Includes insights from world-leading figures in the pharmaceutical industry, healthcare sector, federal funding agencies, regulatory bodies, investment sector, entrepreneurship, intellectual property law, philanthropic organizations, and advocacy groups
• Develops in-depth, original concepts, which have important implications in the understanding of, and search for, potential solutions to the world´s health care crisis

Researchers, advanced students and managers in the pharmaceutical industry and disease foundations. Healthcare professionals, FDA staff, business graduates, anyone interested in medical technology development and scientific innovation

Part I
1. Introduction: the remarkable success story of the development of bortezomib
2. Lessons from the development of bortezomib: the Core Model

Part II
3. The “Core”: when innovation meets leadership
4. “The Bridge”: collaboration is the best catalyst to success
5. “The Periphery”: the efficient use of underused societal resources

Part III
6. Biopharmaceutical intellectual property, financial interests, and the Core Model
7. Global health care crisis, the pharmaceutical industry, and the Core Model
8. The Core Model, innovation, economic growth, development, and policy-making

Part IV
9. Conclusion: the Core Model: a novel economic theory
10. Epilogue: the Core Model and other industries